HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

Olezarsen cut triglycerides 64% and remnant cholesterol 72%, but plaque did not change

Gokhan Can · Mar 30, 2026 · ♥ 10 reactions · 10 comments · original Facebook post
PCSK9, ezetimibe & newer drugsPlaque, CAC & CT angiographyLDL, ApoB & lipid panel
AI summary & key facts

Quotes Ethan Weiss on a surprising null result: at 6 months olezarsen lowered triglycerides 63.9%, remnant cholesterol 71.9% and apoB 16.0% versus placebo with no LDL-C difference, yet there was no difference in plaque at one year. This suggests triglyceride/remnant lowering alone may not shrink plaque.

"I am surprised that nobody is surprised by these results. It feels quite earth-shattering to me but what do I know?

*At 6 months, olezarsen reduced triglycerides by 63.9%, remnant cholesterol by 71.9%, and apolipoprotein B by 16.0% over placebo, with no difference in LDL-C. *

And yet no difference in plaque at all at one year? None? So many questions and so few answers but I think this is one of the most interesting null results I have seen in a long time."

Post on X · Ethan J. WeissEthan J. Weiss on XI am surprised that nobody is surprised by these results. It feels quite earth-shattering to me but what do I know? At 6 months, olezarsen reduced triglycerides by 63.9%, remnant cholesterol by 71.9%, and apolipoprotein B by 16.0% over placebo, with no difference in LDL-C. And… https://t.co/NxT8VDceTrx.com

Research cited

#triglycerides#cholesterol#plaque
← newer: Statins cut deaths 31% in people 80+, showing absolute benefolder: US county cancer incidence map shared without analysis →